PL3360864T3 - Związek pirymidynowy - Google Patents

Związek pirymidynowy

Info

Publication number
PL3360864T3
PL3360864T3 PL16853686T PL16853686T PL3360864T3 PL 3360864 T3 PL3360864 T3 PL 3360864T3 PL 16853686 T PL16853686 T PL 16853686T PL 16853686 T PL16853686 T PL 16853686T PL 3360864 T3 PL3360864 T3 PL 3360864T3
Authority
PL
Poland
Prior art keywords
pyrimidine compound
pyrimidine
compound
Prior art date
Application number
PL16853686T
Other languages
English (en)
Inventor
Hidenori Kimura
Hitoshi Ban
Yoshiaki Isobe
Hitoshi Watanabe
Original Assignee
Sumitomo Dainippon Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co., Ltd. filed Critical Sumitomo Dainippon Pharma Co., Ltd.
Publication of PL3360864T3 publication Critical patent/PL3360864T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Oncology (AREA)
PL16853686T 2015-10-07 2016-10-06 Związek pirymidynowy PL3360864T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015199750 2015-10-07
EP16853686.0A EP3360864B1 (en) 2015-10-07 2016-10-06 Pyrimidine compound
PCT/JP2016/079756 WO2017061532A1 (ja) 2015-10-07 2016-10-06 ピリミジン化合物

Publications (1)

Publication Number Publication Date
PL3360864T3 true PL3360864T3 (pl) 2021-10-25

Family

ID=58487860

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16853686T PL3360864T3 (pl) 2015-10-07 2016-10-06 Związek pirymidynowy
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL21164640.1T PL3868741T3 (pl) 2015-10-07 2016-10-06 Kompozycja zawierająca związek pirymidynowy i antygen pochodzący od patogenu

Country Status (20)

Country Link
US (5) US10632192B2 (pl)
EP (2) EP3868741B1 (pl)
JP (3) JP6769976B2 (pl)
KR (1) KR102651207B1 (pl)
CN (1) CN108290845B (pl)
AU (1) AU2016334826B2 (pl)
CA (1) CA3001283C (pl)
CY (1) CY1124542T1 (pl)
DK (2) DK3360864T3 (pl)
ES (2) ES2870679T3 (pl)
FI (1) FI3868741T3 (pl)
HU (2) HUE064322T2 (pl)
MY (1) MY194902A (pl)
PH (1) PH12018500755A1 (pl)
PL (2) PL3360864T3 (pl)
PT (2) PT3868741T (pl)
RU (1) RU2759917C2 (pl)
SG (1) SG11201802832UA (pl)
TW (1) TWI718188B (pl)
WO (1) WO2017061532A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017061532A1 (ja) 2015-10-07 2017-04-13 大日本住友製薬株式会社 ピリミジン化合物
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
EP3554474B1 (en) * 2016-12-16 2023-12-06 Baxter International Inc. Micafungin compositions
EP3603619B1 (en) * 2017-03-29 2025-08-13 Sumitomo Pharma Co., Ltd. Vaccine adjuvant formulation
WO2019123339A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CA3107409A1 (en) 2018-07-23 2020-01-30 Japan As Represented By Director General Of National Institute Of Infectious Diseases Composition containing influenza vaccine
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
CA3121613A1 (en) * 2018-12-26 2020-07-02 Sumitomo Dainippon Pharma Co., Ltd. Preparation including vaccine adjuvant
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
CN113966326A (zh) * 2019-04-05 2022-01-21 大日本住友制药株式会社 水溶性佐剂
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021192393A1 (en) * 2020-03-27 2021-09-30 Path Malaria transmission-blocking vaccines
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
JP7686091B2 (ja) 2021-06-23 2025-05-30 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
JP7651018B2 (ja) 2021-06-23 2025-03-25 ギリアード サイエンシーズ, インコーポレイテッド ジアシルグリセロールキナーゼ調節化合物
MX2023014762A (es) 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.
CN121311513A (zh) * 2023-04-12 2026-01-09 住友制药株式会社 葡聚糖与tlr7激动剂的缀合物
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240243A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ES2221414T3 (es) 1998-08-27 2004-12-16 Sumitomo Pharmaceuticals Company, Limited Derivados de pirimidina.
JP2007514644A (ja) 2003-04-10 2007-06-07 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応を向上させる方法および組成物
US7799800B2 (en) 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
PE20091236A1 (es) * 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
FR2924024B1 (fr) * 2007-11-27 2012-08-17 Centre Nat Rech Scient Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
TR201802083T4 (tr) 2008-10-24 2018-03-21 Glaxosmithkline Biologicals Sa Lipidatlı imidazokinolin türevleri.
FR2937549B1 (fr) * 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
JP5206513B2 (ja) 2009-03-12 2013-06-12 オムロンヘルスケア株式会社 機能追加モジュール
AU2010250923A1 (en) * 2009-05-21 2011-11-17 Astrazeneca Ab Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
MX2012001524A (es) 2009-08-07 2012-02-29 Glaxosmithkline Biolog Sa Derivados de oxoadenina lipidada.
JP2013525431A (ja) 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成tlr7アゴニストのリン脂質結合体の使用
US9242980B2 (en) * 2010-08-17 2016-01-26 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
WO2012067269A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) * 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
WO2012067268A1 (en) * 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
CN103827115A (zh) 2011-09-20 2014-05-28 弗·哈夫曼-拉罗切有限公司 咪唑并吡啶化合物、组合物和使用方法
JP6184423B2 (ja) * 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
WO2017061532A1 (ja) 2015-10-07 2017-04-13 大日本住友製薬株式会社 ピリミジン化合物

Also Published As

Publication number Publication date
KR20180056774A (ko) 2018-05-29
PH12018500755A1 (en) 2018-10-15
US12440560B2 (en) 2025-10-14
AU2016334826A1 (en) 2018-05-10
RU2759917C2 (ru) 2021-11-18
AU2016334826B2 (en) 2020-08-27
JP2021001210A (ja) 2021-01-07
RU2018116351A3 (pl) 2020-02-25
DK3360864T3 (da) 2021-06-14
HUE064322T2 (hu) 2024-03-28
MY194902A (en) 2022-12-22
US20260053911A1 (en) 2026-02-26
TW201718518A (zh) 2017-06-01
PL3868741T3 (pl) 2024-01-29
TWI718188B (zh) 2021-02-11
FI3868741T3 (fi) 2023-10-02
US20210008197A1 (en) 2021-01-14
DK3868741T3 (da) 2023-11-06
JP7195398B2 (ja) 2022-12-23
PT3868741T (pt) 2023-10-19
EP3360864B1 (en) 2021-04-28
HUE055079T2 (hu) 2021-10-28
CA3001283C (en) 2023-10-10
HK1255921A1 (en) 2019-09-06
RU2018116351A (ru) 2019-11-07
KR102651207B1 (ko) 2024-03-25
EP3360864A4 (en) 2019-05-29
WO2017061532A1 (ja) 2017-04-13
EP3360864A1 (en) 2018-08-15
US11911466B2 (en) 2024-02-27
US20180280499A1 (en) 2018-10-04
CY1124542T1 (el) 2022-07-22
CN108290845B (zh) 2021-08-03
JP2022010266A (ja) 2022-01-14
SG11201802832UA (en) 2018-05-30
CN108290845A (zh) 2018-07-17
US11266738B2 (en) 2022-03-08
EP3868741B1 (en) 2023-08-30
JPWO2017061532A1 (ja) 2018-08-02
US10632192B2 (en) 2020-04-28
PT3360864T (pt) 2021-06-02
ES2960724T3 (es) 2024-03-06
ES2870679T3 (es) 2021-10-27
US20220226468A1 (en) 2022-07-21
US20240245766A1 (en) 2024-07-25
CA3001283A1 (en) 2017-04-13
EP3868741A1 (en) 2021-08-25
JP6769976B2 (ja) 2020-10-14

Similar Documents

Publication Publication Date Title
FIC20230006I1 (fi) Vutrisiraani
PL3360864T3 (pl) Związek pirymidynowy
EP3578560A4 (en) QUINAZOLINE COMPOUND
DK3627029T3 (da) Manipulationssikret låg
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
PT3298027T (pt) Compostos depsipéptidos antelmínticos
IL265166B (en) Anti-influenza virus pyrimidine derivatives
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
KR20180084876A (ko) 내플라즈마성 부재
EP3435660A4 (en) HEAD-MOUNTED DISPLAY
EP3564216A4 (en) PYRIMIDINE DERIVATIVE
SMT202200173T1 (it) Composti
EP3372588A4 (en) pyrimidine
LT3362444T (lt) Junginiai
DK3597189T3 (da) Krystallinske forbindelser
DE112015006486A5 (de) Inkubationsrinne
BR112018001062A2 (pt) compostos inovadores
EP3372589A4 (en) pyrimidine derivative
DK3347403T3 (da) Polyalkoxyfedtforbindelse
EP3346592A4 (en) Rotating machine
DE102015206660A8 (de) Plattenaufteilanlage
LT3331885T (lt) Junginiai
EP3454107A4 (en) HEAD MOUNTED DISPLAY
DE112015005905A5 (de) Gurtschlossbringer
DK3630729T3 (da) Pyrimidinforbindelse